INNSBRUCK, AUSTRIA — MED-EL has acquired two gene therapy programs from Rescue Hearing Inc. targeting genetic causes of hearing and balance disorders. The programs address genetic disorders associated with mutations in the MYO7A and STRC genes....
No actionable change — this is an early-stage corporate acquisition of pre-clinical or early-clinical gene therapy programs; no treatment is available to patients or clinicians at this time.
A major cochlear implant manufacturer moving into gene therapy signals a potential industry shift toward curative biological treatments for genetic hearing loss, which could reshape long-term patient care pathways in audiology.
- 01MED-EL acquired two inner ear gene therapy programs from Rescue Hearing Inc.
- 02Programs target hearing and balance disorders caused by mutations in the MYO7A and STRC genes.
- 03MYO7A mutations are associated with Usher syndrome type 1B; STRC mutations are one of the most common causes of mild-to-moderate hereditary hearing loss.
- 04This marks a strategic expansion for MED-EL beyond its core hearing implant business into biological/genetic therapeutics.
- 05No clinical availability timeline or trial data was disclosed in the announcement.
MED-EL acquired two inner ear gene therapy programs targeting MYO7A and STRC gene mutations from Rescue Hearing Inc.
press releasesupportedThe gene therapy programs target hearing and balance disorders caused by MYO7A and STRC mutations.
press releasepartially supported